Analyst Price Targets — MNMD
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| October 13, 2025 9:56 am | Ami Fadia | Needham | $28.00 | $11.81 | TheFly | Mind Medicine initiated with a Buy at Needham |
| March 7, 2025 12:35 pm | — | Robert W. Baird | $16.00 | $6.83 | TheFly | Mind Medicine price target lowered to $16 from $27 at Baird |
| September 16, 2024 8:07 am | Sumart Kulkami | Canaccord Genuity | $14.00 | $6.45 | StreetInsider | MindMed (MNMD) PT Lowered to $14 at Canaccord Genuity |
| June 5, 2024 6:14 am | Brian Abrahams | RBC Capital | $22.00 | $8.25 | StreetInsider | RBC Capital Reiterates Outperform Rating on MindMed (MNMD) |
| May 13, 2024 7:36 am | Francois Brisebois | Oppenheimer | $20.00 | $8.61 | StreetInsider | MindMed (MNMD) PT Lowered to $20 at Oppenheimer |
| November 16, 2022 6:10 am | — | RBC Capital | $5.00 | $2.86 | Benzinga | RBC Capital Initiates Coverage On Mind Medicine with Outperform Rating, Announces Price Target of $5 |
Latest News for MNMD
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD - Get Free Report) saw a significant increase in short interest during the month of December. As of December 31st, there was short interest totaling 15,054,621 shares, an increase of 19.4% from the December 15th total of 12,612,667 shares. Currently, 15.6% of the company's stock are sold short. Based on
Mind Medicine (MindMed) Inc. (MNMD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD - Get Free Report) CEO Robert Barrow sold 25,791 shares of the business's stock in a transaction on Friday, December 26th. The shares were sold at an average price of $13.15, for a total transaction of $339,151.65. Following the sale, the chief executive officer directly owned 778,477 shares in the
MNMD has surged 101% in six months with MM120 advancing in phase III for GAD and MDD. Pivotal readouts are slated for 2026.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD - Get Free Report) has received a consensus rating of "Buy" from the twelve analysts that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, eight have assigned a buy rating and three have given a strong buy rating to the
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for MNMD.
Senate Trading
No Senate trades found for MNMD.
U.S. House Trading
No House trades found for MNMD.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.